



**Access to Medicines & Investor Privileges under Free Trade Agreements:
*The Case of Eli Lilly***

Catered Lunch*

(*vegetarian and halal options will be available)

Sunday, 10 March 2013, 12:35 PM

**Holiday Inn Atrium, 317 Outram Road
Seletar Room 3, Level 3**

(5 minute walk from Grand Copthorne Waterfront Hotel)

Please RSVP to jboehner@citizen.org

Eli Lilly is seeking \$100 million in compensation from Canadian taxpayers in the first attempt by a patent-holding pharmaceutical corporation to use U.S. “trade” agreement investor privileges as a tool to push for greater monopoly patent protections, which increase the cost of medicines for consumers and governments. Eli Lilly launched its NAFTA investor-state case after Canadian courts invalidated Eli Lilly’s patent for a drug after determining that the medicine had failed to deliver the benefits the firm promised when obtaining the patent. In its formal notice of intent, Eli Lilly makes clear that it is using the investor-state regime to not only challenge the invalidation of its particular patent, but also Canada’s “promise doctrine.” The “promise doctrine” prevents spurious patent monopolies and safeguards the quality of the system.

A panel of experts will discuss the growing concern of the public health community about how investment provisions could threaten countries’ ability to determine patent standards and provide access to affordable medicines.

Expert Panelists:

- **Lori Wallach**, Director, Public Citizen’s Global Trade Watch
Wallach will summarize the claims raised in the recent NAFTA investor-state case filed by Eli Lilly against Canada alleging that the denial of a medicine patent is an expropriation of investor rights.
- **Dr. Burcu Kilic**, Legal Counsel, Public Citizen’s Access to Medicines Campaign
Dr. Kilic will present on the utility standard in Canadian law, the promise doctrine, and its application to pharma/biotech inventions.
- **Sanya Reid Smith**, Legal Advisor and Senior Researcher, Third World Network
Reid Smith will discuss the possible implications of other TPP investment chapter provisions for intellectual property.

Sponsored by Public Citizen & Third World Network